Showing results (71-80 of 104) with videos related to

Sort By:
Pageof 11
RMD Open|April 5, 2024
Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT registerTatjana Rudi, Vera Zietemann, Yvette Meissner, et al.
Arthritis Research & Therapy|April 8, 2006
Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics registerJoachim Listing, Anja Strangfeld, Rolf Rau, et al.
Arthritis Research & Therapy|August 7, 2016
Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritisYvette Meissner, Angela Zink, Jörn Kekow, et al.
Arthritis Care & Research|September 4, 2019
Disease Burden of Patients With Osteoarthritis: Results of a Cross-Sectional Survey Linked to Claims DataJohanna Callhoff, Katinka Albrecht, Imke Redeker, et al.
Rheumatology (Oxford, England)|September 24, 2010
Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registersAnja Strangfeld, Kimme Hyrich, Johan Askling, et al.
Therapeutic Advances in Musculoskeletal Disease|December 7, 2020
The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based studyImke Redeker, Britta Siegmund, Kamran Ghoreschi, et al.
The Journal of Rheumatology|January 6, 2006
Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitisAngela Zink, Katja Thiele, Doerte Huscher, et al.
Rheumatology (Oxford, England)|August 15, 2019
Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis-results from a JIA biologic registryPaula Drechsel, Katrin Stüdemann, Martina Niewerth, et al.
Annals of the Rheumatic Diseases|June 8, 2010
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatologyWilliam G Dixon, Loreto Carmona, Axel Finckh, et al.
The Journal of Rheumatology|August 1, 2022
The Sensitivity to Change of the ASAS Health Index in an Observational Real-Life Cohort StudyAnne C Regierer, Anja Weiß, Uta Kiltz, et al.
Pageof 11